Journal: bioRxiv
Article Title: A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy
doi: 10.1101/2025.09.28.679024
Figure Lengend Snippet: PS19 mice received either 1.5mg/mouse anti-PD-L1 blocking antibody or isotype control at 5-6 months of age. Non-transgenic (WT) littermates were used as a negative control. (a) Cortical and (b) hippocampal levels of S404 hyperphosphorylated Tau protein were measured using HTRF on days 14 and 28 following injection. (c) CSF and (d) serum levels of NfL were measured using ELISA or SIMOA, respectively. n=5-6 per group; one-way ANOVA followed by Fischer post-hoc test; error bars represent mean ± SEM; **, p< 0.01; ***, p< 0.001; ns = non-significant, between indicated groups.
Article Snippet: Serum NfL was quantified using the human NfL kit on the SIMOA platform (Quanterix) according to the manufacturer’s instructions.
Techniques: Blocking Assay, Control, Transgenic Assay, Negative Control, Injection, Enzyme-linked Immunosorbent Assay